Skip to main navigation

Skip to Content

Overview
Stock Information
SEC Filings
Corporate Governance
Company
Contact Us
ImmunityBio.com

Press Releases

Press Releases

Year

ImmunityBio to Participate in the Jefferies Global Healthcare Conference

May 22, 2023

National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome

Apr 25, 2023

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University

Apr 24, 2023

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU

Feb 16, 2023

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

Feb 15, 2023

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

Jan 19, 2023

IR Tools

© 2023 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘Conkwest’, ‘haNK’, ‘taNK’, ‘vaNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Neukosome’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Infacell’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, Inc.

Anktiva is a trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons